Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration

Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Ashish, Churkin, Alex, Barash, Danny, Cotler, Scott J, Shlomai, Amir, Etzion, Ohad, Dahari, Harel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045946/
https://www.ncbi.nlm.nih.gov/pubmed/35493122
http://dx.doi.org/10.1093/ofid/ofac157
Descripción
Sumario:Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 14 of therapy can identify patients for shortening therapy duration.

Ejemplares similares